Neuland Laboratories Limited reported a robust Q4 FY26 performance with total income reaching INR 788.7 crore, a 134.9% increase year-over-year. Driven by commercial CMS projects, the company achieved a full-year revenue of INR 2,053.1 crore, reflecting 37.1% annual growth. Management highlighted long-term strategic investments in peptide manufacturing and R&D, signaling confidence in sustainable growth despite inherent quarterly revenue volatility in the CDMO sector.
Record Quarterly Performance
Neuland Laboratories concluded FY26 on a high note, with the fourth quarter acting as a significant contributor to the year’s success. Total income for the quarter ended March 31, 2026, was INR 788.7 crore, compared to INR 335.8 crore in the same period last year. Operating margins also saw a sharp increase, with an EBITDA of INR 319.4 crore and a margin of 40.5%.
Annual Financial Summary
For the full FY26, the company reported revenue of INR 2,053.1 crore, marking a 37.1% growth over FY25‘s INR 1,497.3 crore. EBITDA for the year stood at INR 603.4 crore, with a margin of 29.4%. The profit after tax for the full year reached INR 363.1 crore, resulting in an EPS of INR 283.01.
Strategic Investments in Peptides
The management emphasized the importance of its large-scale peptide commercial facilities, which are on track to become operational by July 2026. This investment is central to Neuland’s strategy to move into more differentiated, high-value API spaces. With 8 to 10 peptide programs currently in the development pipeline, the company expects this sector to serve as a significant growth engine over the next five years.
Navigating Business Volatility
Addressing investor concerns regarding revenue lumpiness, management maintained that such volatility is inherent to the CDMO business model, particularly as new, high-value molecules enter the portfolio. To mitigate risks, the company is prioritizing cost governance, process standardization, and capital discipline. Leadership reiterated that while individual quarters may show variability, the company remains confident in achieving its long-term aspirational growth targets of 18% to 20% CAGR.
Operational Outlook
Looking ahead, Neuland is shifting its capital allocation mindset to support long-term scalability. This includes strengthening internal R&D capabilities and ensuring that manufacturing infrastructure is ready to accommodate demand from both existing customers and potential big pharma partnerships. The company continues to monitor global market dynamics and supply chain factors to ensure operational resilience and sustainable value creation.
Source: BSE
